Decision Analytic Modeling in Health Economics
Also known as: decision analysis, decision tree, decision model, health economic model
Decision analytic modeling is a systematic framework for comparing health interventions by integrating evidence on probabilities, outcomes, costs, and patient preferences into a quantitative model. Developed by Pauker and Kassirer in 1975, decision analysis structures clinical uncertainty and economic trade-offs, enabling transparent comparison of treatment options and identification of optimal strategies. Used in health technology assessment, clinical practice guideline development, and resource allocation decisions.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
When comparing health interventions and decision-makers need systematic evidence integration. Decision analysis is standard for: (1) clinical practice guideline development (comparing treatment strategies). (2) health technology appraisal (reimbursement decisions). (3) resource allocation (prioritizing interventions). (4) research prioritization (identifying where more data would most improve decision confidence). (5) patient counseling (shared decision-making tools). Used when: multiple options exist, outcomes uncertain, preferences and costs matter, and transparent framework is valued. Not needed for: straightforward clinical comparisons with clear winner (e.g., two drugs with identical efficacy, one much cheaper—intuitive decision); rare outcomes where modeling adds little value.
Strengths & limitations
- Integrates evidence transparently: probabilities, outcomes, costs, utilities explicitly stated and linked, enabling stakeholder critique and updating as evidence evolves.
- Handles uncertainty systematically: sensitivity and probabilistic analysis quantify impact of uncertainty on decisions, guiding where more research is most valuable.
- Facilitates communication: decision tree visualizes problem structure; stakeholders (clinicians, patients, payers) understand trade-offs and value judgments.
- Flexible: accommodates diverse evidence types (RCTs, observational, expert opinion) and can be updated as new data emerge.
- Parameter uncertainty: model is only as good as input probabilities and utilities; if data are sparse or biased, model output unreliable.
- Assumes rational decision-making: expected value approach assumes decision-makers are risk-neutral; actual preferences often non-linear (loss aversion, hope bias).
- Simplifies reality: model necessarily abstracts disease complexity; important clinical factors may be omitted or averaged, losing patient-specific nuance.
- Requires substantial data: building rigorous model demands data on probabilities (trials, registries), utilities (preference surveys), and costs (accounting records); data often incomplete.
- GIGO (Garbage In, Garbage Out): if input assumptions are wrong or controversial, output is misleading despite mathematical rigor.
Frequently asked
What is the difference between a decision tree and a Markov model?
Decision tree: short time horizon (e.g., immediate post-treatment period), single pathway per decision arm, each branch terminal endpoint. Used for acute decisions (test or not, treat or not) with outcomes occurring within trial timeframe. Markov model: long time horizon (chronic disease over years/decades), patients cycle through health states repeatedly, transitions defined probabilistically. Used when disease progression over time is relevant. Often combined: decision tree determines initial choice (e.g., screen yes/no); then Markov model projects long-term consequences for chosen arm.
How are utilities assigned if no direct data available?
Methods: (1) Use published utility weights (EQ-5D, SF-6D, HUI tariffs) for similar health states. (2) Conduct focused utility elicitation (time trade-off, visual analog scale, discrete choice) with patient/general population sample. (3) Expert judgment: clinicians estimate, acknowledging uncertainty. (4) Mapping: if trial collected QoL data on disease-specific scales, use published mapping algorithms to convert to utilities. Data gaps should trigger sensitivity analysis: vary utilities ±20% and see if decision changes.
Why is sensitivity analysis so important in decision models?
Model output (ICER, recommendation) depends on input parameters (probabilities, utilities, costs). Parameters are estimated with uncertainty. Sensitivity analysis tests robustness: if decision is robust to plausible parameter ranges, confidence is high; if decision flips with small changes, sensitivity is high and decision is fragile. One-way sensitivity (vary one param), two-way, and probabilistic (vary all simultaneously) show which parameters drive results. This guides where more data collection is most valuable.
What is 'threshold analysis' and when is it useful?
Threshold analysis identifies break-even values: 'At what parameter value does the decision switch?' Example: 'If treatment efficacy is ≥60%, intervention is cost-effective at £20,000/QALY threshold; below 60%, not cost-effective.' Thresholds guide interpretation: if estimated efficacy is 70% (above threshold), recommendation is robust; if 58% (near threshold), more data on efficacy needed. Thresholds also inform pricing: company can calculate, 'At what price is our drug cost-effective for payer?' Cost thresholds drive negotiation.
How does expected value differ from expected utility?
Expected value: expected cost/QALY outcome (mathematical average). Expected utility: value adjusted for individual risk preferences. Example: decision with 50% chance of QALY outcome 10 and 50% chance of 0 (expected value = 5 QALYs). Risk-neutral person values this equally to guaranteed 5 QALYs. Risk-averse person may prefer certain 3 QALY over risky gamble; their expected utility < expected value. Most decision models use expected value (risk-neutral assumption); shared decision-making models may adjust for patient risk preference.
Sources
- Pauker, S. G., & Kassirer, J. P. (1975). Therapeutic Decision Making: A Cost-Benefit Analysis. New England Journal of Medicine, 293(5), 229-234. DOI: 10.1056/NEJM197507312930505 ↗
- Briggs, A. H., Claxton, K., & Sculpher, M. J. (2006). Decision Modelling for Health Economic Evaluation. Oxford: Oxford University Press. link ↗
- Drummond, M. F., Sculpher, M. J., Claxton, K., Stoddart, G. L., & Torrance, G. W. (2015). Methods for the Economic Evaluation of Health Care Programmes (4th ed.). Oxford: Oxford University Press. link ↗
How to cite this page
ScholarGate. (2026, June 4). Decision Analytic Modeling in Health Economics. ScholarGate. https://scholargate.app/en/health-economics/decision-analytic-modeling
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
- Budget Impact AnalysisHealth Economics↔ compare
- Cost-Benefit AnalysisHealth Economics↔ compare
- Cost-Effectiveness AnalysisHealth Economics↔ compare
- Markov Model in Health EconomicsHealth Economics↔ compare
- Quality-Adjusted Life YearHealth Economics↔ compare